Role of ketogenic metabolic therapy in malignant glioma: A systematic review
Introduction
Malignant glioma is the most common primary brain tumor (Ostrom et al., 2014, Crocetti et al., 2012). Glioblastoma multiforme (GBM), the most frequent and most aggressive type of glioma (Tanaka et al., 2013, Venur et al., 2015), carries an exceptionally poor prognosis. With a median overall survival (OS) between 12 and 15 months from time of diagnosis (Wen and Kesari, 2008, Carlsson et al., 2014) and a 5-year survival rate of less than 5% (Carlsson et al., 2014) despite maximal treatment, there is a pressing need to identify and implement more efficacious therapies.
The current standard of care (SOC) for glioblastoma patients consists of maximal safe resection, followed by radiotherapy and concurrent chemotherapy with Temozolomide (TMZ) (Venur et al., 2015, Alifieris and Trafalis, 2015, Anton et al., 2012). Tumor-associated symptoms arising from peritumoral edema are generally managed with glucocorticoids (Dietrich et al., 2011, Schiff et al., 2015, Roth et al., 2010). Anti-angiogenic treatment with bevacicumab (Avastin) has shown to provide some benefit on quality of life and progression-free survival (PFS), but not OS (Khasraw et al., 2014, Chinot et al., 2014, Gilbert et al., 2014). Despite substantial clinical research efforts over the past decades, therapeutic progress has been marginal (Frosina, 2015); added benefits from TMZ (Hart et al., 2013) and bevacizumab (Khasraw et al., 2014) are modest and patient OS remains poor. Apart from provoking classical side effects associated with anti-cancer therapy, the current SOC bears additional CNS-specific side effects, including cognitive decline and structural brain changes associated with chemotherapy and radiation (Prust et al., 2015, Kaiser et al., 2014, Monje and Dietrich, 2012, Dietrich et al., 2008, Dietrich, 2010). While putative genetic mutations and abnormal signaling pathways are implicated in disease pathogenesis (Tanaka et al., 2013, Bastien et al., 2015), GBMs are highly heterogeneous in nature (Aum et al., 2014, Prados et al., 2015), i.e. consisting of distinct cellular subpopulations with differing genetic mutations and gene expression profiles (Parsons et al., 2008, Brennan et al., 2013, Crespo et al., 2015). Tumor heterogeneity and rapidly evolving resistance mechanisms have been considered as likely reasons for the lack of durable responses with novel targeted therapies that usually rely on blocking specific signaling pathways.
A hallmark of cancer (Hanahan and Weinberg, 2011), tumor cell energy metabolism is usually aberrantly shifted towards “aerobic glycolysis” (Seyfried et al., 2014). Following glycolysis, pyruvate is fermented to lactate despite cellular availability of oxygen – a phenomenon coined as the “Warburg effect” following the discoveries of the German physician, biochemist, and Nobel laureate Otto Warburg nearly a century ago (Warburg and Posener, 1924, Warburg and Dickens, 1930). Malignant glioma cells critically depend on glucose as the main energy source to survive and sustain their aggressive properties (Jelluma et al., 2006). Like most cancers (Fulda et al., 2010), GBMs usually have dysregulated mitochondria, impeding efficient TCA cycle and oxidative phosphorylation activities necessary for aerobic ATP production (Seyfried et al., 2014, Seyfried et al., 2011). This is not only reflected by abnormal proteomic changes within the mitochondrial metabolic and apoptotic regulatory machinery (Deighton et al., 2014, Guntuku et al., 2016), but also by abundant ultrastructural mitochondrial pathology such as cristolysis and mitochondrial swelling found in human astrocytoma and GBM tumor cells (Deighton et al., 2014, Guntuku et al., 2016, Arismendi-Morillo and Castellano-Ramirez, 2008). Most tumor cells thus rely on generating ATP mainly through the comparatively inefficient cytosolic glycolysis pathway. In a compensatory manner, glycolytic gene expression and associated glycolytic rates are commonly upregulated in malignant glioma (Oudard et al., 1997, Oudard et al., 1996, Ru et al., 2013, Sanzey et al., 2015). Numerous preclinical studies have confirmed this compelling glucose-dependency (Seyfried et al., 2011, Seyfried et al., 2015, Varshneya et al., 2015, Woolf and Scheck, 2015), corroborated by clinical findings identifying hyperglycemia as a negative predictor of OS in GBM patients (Adeberg et al., 2015, Tieu et al., 2015, Mayer et al., 2014, Derr et al., 2009, McGirt et al., 2008, Liu et al., 2015).
Despite ample evidence of abnormally regulated energy metabolism in malignant glioma (Seyfried et al., 2011, Ru et al., 2013), nutritional strategies targeting glycemic modulation to exploit the observed tumor glucose-dependency have not yet been thoroughly investigated in clinical trials and existing clinical data is limited (Strowd and Grossman, 2015). Notably, it has been hypothesized that the current SOC, while evidently providing at least temporary modest benefit for symptomatic management and OS, might actually contribute to tumor progression in the long-term (Seyfried et al., 2011, Seyfried et al., 2015, Maroon et al., 2015). For instance, recent evidence suggests that TMZ might cause a hypermutational phenotype with concerns of increased tumor aggressiveness (Yip et al., 2009). Moreover, it has been speculated that tissue injury from surgery and standard cytotoxic treatment can promote persistent neuro-inflammation within the tumor microenvironment (Lee et al., 2010, Monje et al., 2007, Brandsma et al., 2008), potentially driving tumor progression (Kyritsis et al., 2011, Yeung et al., 2013). Beside these major concerns, standard treatments are usually non-specific resulting in collateral brain tissue damage while providing inflammation-induced proliferative and pro-angiogenic stimuli to tumor cells. Moreover, recent evidence suggests that glucocorticoids – administered to nearly all glioma patients throughout the course of their disease for edema-related symptom management (Chang et al., 2005) – in their immunosuppressive and anti-proliferative nature might actually interfere with cytotoxic treatment efficacy and diminish OS in patients with GBM (Wong et al., 2015, Pitter et al., 2016). Glucocorticoids also contribute to hyperglycemia (Harris et al., 2013, Pasternak et al., 2004, Lukins and Manninen, 2005), creating an even more permissive metabolic environment for tumor growth (Seyfried et al., 2015). Lastly, bevacizumab treatment may foster metabolic-reprogramming of GBMs toward anaerobic metabolism, boosting GBM invasive potential in an adaptive manner (Fack et al., 2015).
Increasing recognition of the metabolic peculiarities of cancer has prompted investigations of nutritional strategies targeting glycemic modulation in cancer treatment, predominantly through use of high-fat and low-carbohydrate diets (ketogenic diets; KDs), but also caloric restriction (CR), intermittent fasting (IF) and other combinatorial dietary protocols (Strowd and Grossman, 2015, Simone et al., 2013). All of these strategies induce a physiological state of systemic ketosis that metabolically compensates for the therapeutic reduction of carbohydrate intake and concurrent decrease in blood glucose levels (Simone et al., 2013). Both glycemic reduction and systemic ketosis are established key metabolic correlates of these nutritional strategies and are thought to mediate their therapeutic efficacy (Seyfried et al., 2015, Simone et al., 2013). Thus, to simplify the terminology and to emphasize their underlying mechanistic similarities and known bioactive potential, we here propose – and henceforth utilize – the umbrella term “ketogenic metabolic therapy (KMT)” when collectively referring to these strategies.
A role for KMT is emerging in the field of neuro-oncology. Numerous preclinical studies have investigated KDs for malignant glioma treatment (Seyfried et al., 2015, Varshneya et al., 2015, Woolf and Scheck, 2015, Maroon et al., 2015, Maroon et al., 2013, Seyfried et al., 2012). KDs have previously been successfully utilized for systemic treatment of epilepsy (Neal et al., 2008), obesity (Moreno et al., 2014), diabetes (Hussain et al., 2012), and cancer (Seyfried et al., 2014, Simone et al., 2013). Originally applied in intractable childhood epilepsy treatment (Freeman and Kossoff, 2010), successful clinical use of a KD-based KMT to treat malignant glioma was first reported in 1995 (Nebeling et al., 1995). Since then, an array of in vivo rodent work has suggested efficacy and safety of this dietary intervention for malignant glioma treatment (Seyfried et al., 2015, Woolf and Scheck, 2015). Moreover, emerging clinical reports indicate potential benefits of KMT in brain tumor patients, including case reports of tumor regression or sustained tumor control (Nebeling et al., 1995, Zuccoli et al., 2010) and a cohort study suggesting prolonged overall survival from a combinatorial KMT added to standard treatment (Han et al., 2014).
After reviewing putative KMT-mediated anti-neoplastic effects and relevant preclinical studies, the aim of this study was to provide a comprehensive and systematic review of both published clinical literature as well as ongoing clinical trials, focusing our analysis on evaluating evidence for a potential therapeutic value of KMT as a treatment option in malignant glioma. Moreover, we aimed to identify areas in need of further exploration and discuss potential strategies for future clinical trial design in order to advance this young field of investigation.
Section snippets
Materials and methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009) to screen and analyze all published clinical literature and ongoing clinical trials investigating KMT as an anti-neoplastic strategy in malignant glioma. A systematic search was conducted in November 2015 and updated up until July 2016, screening the index databases PubMed/MEDLINE, EMBASE, Cochrane CENTRAL and Google Scholar for published clinical reports, as well as the
Results
The preclinically observed anti-neoplastic effects of KMT have sparked particular interest in neuro-oncology (Woolf and Scheck, 2015, Strowd and Grossman, 2015, Maroon et al., 2015, Maroon et al., 2013, Seyfried et al., 2003, Seyfried et al., 2008, Seyfried et al., 2009, Woolf and Scheck, 2012, Strowd et al., 2015). Neuroprotective and anti-oxidative properties of ketone bodies (KBs) (Maalouf et al., 2009) in conjunction with selective starvation of malignant glioma cells (Seyfried et al., 2009
Discussion
The current literature and preliminary results from ongoing clinical trials suggest safety and feasibility of KMT in malignant glioma. Moreover, emerging data points to a potential anti-neoplastic effect and possible clinical benefit from KMT (Table 2B). Evidence for clinical utility of KMT is still limited in this newly evolving field and should thus be carefully interpreted; several of the studies reviewed here have small sample sizes and other methodological limitations such as heterogeneity
Conclusions
An array of preclinical studies demonstrates efficacy and safety of KMT for malignant glioma treatment. Early clinical studies suggest KMT is safe and feasible in brain cancer patients, with some encouraging indications of potential anti-neoplastic effects and clinical utility in malignant glioma treatment. Furthermore, several ongoing clinical trials support the notion that KMT is a potential novel treatment strategy that could be combined with existing anti-neoplastic treatments for malignant
Conflicts of interest
None (all authors).
All authors have read and approved the final version of this article.
Acknowledgements
The authors would like to thank Dr. Thomas Seyfried (Dept. of Biology, Boston College, MA, USA) for a very stimulating and insightful discussion on the topic. They further thank Dr. Dong Le (Charité – University Medicine Berlin, Berlin, Germany) for his help with translation of a Chinese article.
S.F.W. received a travel grant from the German National Academic Foundation (Studienstiftung des Deutschen Volkes).
References (161)
- et al.
Glioblastoma multiforme: pathogenesis and treatment
Pharmacol. Ther.
(2015) - et al.
Glioblastoma multiforme: overview of current treatment and future perspectives
Hematol. Oncol. Clin. North Am.
(2012) - et al.
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Lancet Oncol.
(2008) - et al.
The somatic genomic landscape of glioblastoma
Cell
(2013) Dietary protein, growth factors, and cancer
Am. J. Clin. Nutr.
(2007)- et al.
Molecular and genomic alterations in glioblastoma multiforme
Am. J. Pathol.
(2015) - et al.
Epidemiology of glial and non-glial brain tumours in Europe
Eur. J. Cancer
(2012) - et al.
Ketosis and the ketogenic diet, 2010: advances in treating epilepsy and other disorders
Adv. Pediatr.
(2010) Limited advances in therapy of glioblastoma trigger re-consideration of research policy
Crit. Rev. Oncol. Hematol.
(2015)- et al.
Hallmarks of cancer: the next generation
Cell
(2011)
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes
Nutrition
Neural correlates of chemotherapy-related cognitive impairment
Cortex
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
Lancet Oncol.
Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation
Neuroscience
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
Brain Res. Rev.
Modulation of oxidative stress and mitochondrial function by the ketogenic diet
Epilepsy Res.
Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis
Behav. Brain Res.
The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial
Lancet Neurol.
Ketone bodies as signaling metabolites
Trends Endocrinol. Metab.
The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma
PLoS One
The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma
Acta Oncol.
Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts
Clin. Cancer Res.
Ultrastructural mitochondrial pathology in human astrocytic tumors: potentials implications pro-therapeutics strategies
J. Electron. Microsc. (Tokyo)
Results of the modified atkins diet in patients with recurrent glioma: retrospective review (P4.246)
Neurology
Molecular and cellular heterogeneity: the hallmark of glioblastoma
Neurosurg. Focus
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
Cancer
The role of the Insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link
Front. Endocrinol. (Lausanne)
Regulation of cancer cell metabolism
Nat. Rev. Cancer
Emerging treatment strategies for glioblastoma multiforme
EMBO Mol. Med.
Dietary treatment of intractable epilepsy
Continuum (Minneap Minn)
Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
J. Neurooncol.
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study
Science
Patterns of care for adults with newly diagnosed malignant glioma
JAMA
Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy
Nutr. Metab. (Lond.)
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
N. Engl. J. Med.
Interactions among mitochondrial proteins altered in glioblastoma
J. Neurooncol.
Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma
J. Clin. Oncol.
Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy
Oncologist
Corticosteroids in brain cancer patients: benefits and pitfalls
Expert Rev. Clin. Pharmacol.
Chemotherapy associated central nervous system damage
Adv. Exp. Med. Biol.
Effect of dietary macronutrient composition on AMPK and SIRT1 expression and activity in human skeletal muscle
Horm. Metab. Res.
Associations of insulin resistance and adiponectin with mortality in women with Breast cancer
J. Clin. Oncol.
4-(13)C]β-hydroxybutyrate metabolism in astrocytes and C6 glioblastoma cells
Neurochem. Res.
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Acta Neuropathol.
Targeting mitochondria for cancer therapy
Nat. Rev. Drug Discov.
A randomized trial of bevacizumab for newly diagnosed glioblastoma
N. Engl. J. Med.
A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women
Cancer Epidemiol. Biomarkers Prev.
Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study
J. Clin. Oncol.
Mitochondrial dysfunction in gliomas: pharmacotherapeutic potential of natural compounds
Curr. Neuropharmacol.
Perspective research of the influence of caloric restriction combined with psychotherapy and chemotherapy associated by hybaroxia on the prognosis of patients suffered by glioblastoma multiforme
Zhonghua Yi Xue Za Zhi
Cited by (65)
Cancer
2023, Ketogenic: The Science of Therapeutic Carbohydrate Restriction in Human HealthMetabolic therapy and bioenergetic analysis: The missing piece of the puzzle
2021, Molecular MetabolismOn the Origin of ATP Synthesis in Cancer
2020, iScienceCitation Excerpt :Through their anti-angiogenic, anti-inflammatory, and pro-apoptotic actions, calorie restriction and KD-R can normalize the tumor microenvironment (Zhou et al., 2007; Marsh et al., 2008; Mukherjee et al., 2002, 2004, 2019; Mulrooney et al., 2011; Shelton et al., 2010a; Urits et al., 2012). Maximal therapeutic benefit of glutamine-targeting drugs can be obtained for a broad range of cancers when administered to patients under reduced blood glucose and elevated ketone bodies, i.e., nutritional ketosis (Seyfried et al., 2017; Weber et al., 2019; Klement, 2017; Winter et al., 2017; Poff et al., 2017). Figure 5 summarizes how the simultaneous targeting of glucose and glutamine could help manage tumor growth.
Does nutrition for cancer patients feed the tumour? A clinical perspective
2020, Critical Reviews in Oncology/HematologyCitation Excerpt :It is noteworthy that all seven KD studies which included KB levels showed ketosis, or an increase in KB that was, however, not always linked with a corresponding reduction in blood glucose. Meidenbauer et al. and other suggest maintaining the ‘Glucose Ketone Index’ (the molar ratio of circulating glucose over β-hydroxybutyrate) (Meidenbauer et al., 2015) near one or below to achieve the highest benefit (Zuccoli et al., 2010; Rieger et al., 2014; Schwartz et al., 2015; Winter et al., 2017). The underlying hypothesis for a benefit in cancer is the reduction of signalling through insulin and growth hormone receptors, and an enhancement of FOXO and nuclear factor erythroid 2–related factor 2 (Nrf2) transcription factors.
Hemoglobin A1c in Patients with Glioblastoma—A Preliminary Study
2020, World NeurosurgeryCaprylic (Octanoic) Acid as a Potential Fatty Acid Chemotherapeutic for Glioblastoma
2020, Prostaglandins Leukotrienes and Essential Fatty Acids